Pharmaceuticals
Pharma - API & CRAMS
from 8,371 today
Divis reported very strong Q1FY27 numbers, driven by custom synthesis segment growth and a richer mix, justifying a premium valuation. We retain our Buy rating with a target price of Rs. 9,574.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
